How should I write a semaglutide (GLP1 receptor agonist) prescription, specifying the initial dose, titration schedule, frequency, quantity, and refill instructions?
In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)
When labs buy peptides from Pure Tested Peptides, they are choosing a partner that treats compliance, testing, and transparency as core values rather than afterthoughts
This article reviews the emerging trend of microdosing GLP-1 drugs, examining potential benefits, risks, and the current lack of scientific evidence supporting this approach